Harnessing the anticancer activity of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, using rational combination strategies for breast cancer and other malignancies

被引：0
|
作者：
Annis, A. [1 ]
Ren, J. G. [1 ]
Carvajal, L. A. [1 ]
Santiago, S. [1 ]
Narasimhan, N. [1 ]
Sutton, D. [1 ]
Pairawan, S. S. [2 ]
Guerlavais, V. [1 ]
Meric-Bernstam, F. [2 ]
Aivado, M. [1 ]
机构：
[1] Aileron Therapeut Inc, Cambridge, MA USA
[2] MD Anderson, Invest Canc Therapeut, Houston, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
443 (PB-10
引用
收藏
页码：E143 / E144
页数：2
相关论文
共 29 条
  • [21] Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
    Chang, Yong S.
    Graves, Bradford
    Guerlavais, Vincent
    Tovar, Christian
    Packman, Kathryn
    To, Kwong-Him
    Olson, Karen A.
    Kesavan, Kamala
    Gangurde, Pranoti
    Mukherjee, Aditi
    Baker, Theresa
    Darlak, Krzysztof
    Elkin, Carl
    Filipovic, Zoran
    Qureshi, Farooq Z.
    Cai, Hongliang
    Berry, Pamela
    Feyfant, Eric
    Shi, Xiangguo E.
    Horstick, James
    Annis, D. Allen
    Manning, Anthony M.
    Fotouhi, Nader
    Nash, Huw
    Vassilev, Lyubomir T.
    Sawyer, Tomi K.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (36) : E3445 - E3454
  • [22] Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.
    Meric-Bernstam, Funda
    Saleh, Mansoor N.
    Infante, Jeffrey R.
    Goel, Sanjay
    Falchook, Gerald Steven
    Shapiro, Geoffrey
    Chung, Ki Y.
    Conry, Robert Martin
    Hong, David S.
    Wang, Judy Sing-Zan
    Steidl, Ulrich
    Walensky, Loren D.
    Guerlavais, Vincent
    Payton, Marie
    Annis, D. Allen
    Aivado, Manuel
    Patel, Manish R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924
    Koch, Raphael
    Christie, Amanda L.
    Yoshida, Noriaki
    Ng, Samuel Y.
    Shigemori, Kay
    Morrow, Sara N.
    Van Scoyk, Alexandria
    Horwitz, Steven M.
    Jacobsen, Eric
    Santiago, Solimar
    Ren, Jian-Guo
    Guerlavais, Vincent
    Annis, D. Allan
    Aivado, Manuel A.
    Weinstock, David M.
    [J]. BLOOD, 2017, 130
  • [24] Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma
    Payton, M.
    Pinchasik, D.
    Mehta, A.
    Goel, S.
    Zain, J. M.
    Sokol, L.
    Jacobsen, E.
    Patel, M. R.
    Horwitz, S. M.
    Meric-Bernstam, F.
    Shustov, A.
    Weinstock, D.
    Aivado, M.
    Annis, D. A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [25] ATSP-7041: A Novel Stapled α-Helical Peptide Dual Inhibitor of MDM2 and MDMX Effective In Vivo for p53-Dependent Cancers
    Sawyer, Tomi K.
    [J]. BIOPOLYMERS, 2013, 100 (03) : 236 - 236
  • [26] ATSP-7041, a Dual MDM2 and MDMX Targeting Stapled A-helical Peptide Exhibits Potent in Vitro and in Vivo Efficacy in Xenograft Models of Human Cancer
    Chang, Y.
    Graves, B.
    Guerlavais, V.
    Vassilev, L.
    Packman, K.
    Olson, K.
    Annis, A.
    Tovar, C.
    Nash, H.
    Sawyer, T.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 68 - 69
  • [27] Design, synthesis, biophysical and structure-activity properties of a novel dual MDM2 and MDMX targeting stapled a-helical peptide, ATSP-7041, that exhibits potent in vitro and in vivo efficacy in xenograft models of human cancer
    Guerlavais, V.
    Graves, B.
    Tovar, C.
    Packman, K.
    Olson, K.
    Kesavan, K.
    Gangurde, P.
    Darlak, K.
    Horstick, J.
    Mukherjee, A.
    Baker, T.
    Shi, E.
    Lentini, S.
    Sun, K.
    Irwin, S.
    Feyfant, E.
    To, T.
    Filipovic, Z.
    Elkin, C.
    Pero, J.
    Santiago, S.
    Bruton, T.
    Sawyer, T.
    Annis, A.
    Fotouhi, N.
    Manning, T.
    Nash, H.
    Vassilev, L. T.
    Chang, Y. S.
    Sawyer, T. K.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [28] Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway
    Fan, Yangwei
    Li, Mengya
    Ma, Ke
    Hu, Yuan
    Jing, Jiayu
    Shi, Yu
    Li, Enxiao
    Dong, Danfeng
    [J]. CANCER BIOLOGY & THERAPY, 2019, 20 (05) : 617 - 632
  • [29] Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells
    Fan, Yangwei
    Ma, Ke
    Jing, Jiayu
    Wang, Chuying
    Hu, Yuan
    Shi, Yu
    Li, Enxiao
    Geng, Qianqian
    [J]. JOURNAL OF CANCER, 2020, 11 (01): : 25 - 40
123